Please follow the link below to access Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment on PeerView's website. This program was developed through the collaboration between the United States and Canadian Academy of Pathology (USCAP) and Peerview.
Authors: Rami Komrokji, MD and Cecilia CS Yeung, MD
CME / ABIM MOC 1
Released: March 13, 2023
Valid for credit through: April 12, 2024
Are you prepared to work collaboratively to overcome the complexities of myelodysplastic syndromes (MDS) diagnosis, prognostic assessment, and individualized therapy selection? Find out by joining pathology and hematology-oncology experts in this activity, based on a live symposium, that offers case-based guidance on modern, personalized treatment for patients with different disease presentations. Throughout, the experts illustrate how to address important disease symptoms (such as anemia) and reinforce the core pathology principles for optimized diagnosis and communication of test results with a goal in prodigy enhanced, more personalized care.
Target AudienceThis activity has been designed to meet the educational needs of pathologists, hematologists, oncologists, and other healthcare professionals involved in the management of MDS.
Educational ObjectivesUpon completion of this activity, participants should be better able to:
- Discuss molecular and pathologic features, risk factors, and evidence supporting the use of novel therapeutics to inform diagnostic assessment and personalized care of MDS
- Employ appropriate molecular/pathologic testing to establish a diagnosis of MDS or a specific subtype informed by clinical, molecular, and cytogenetic findings
- Develop collaborative team-based treatment plans for patients with MDS based on molecular testing results, pathologic risk assessment, and current guidelines
DisclosuresPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Rami Komrokji, MD
Vice Chair - Malignant Hematology Section Head - Leukemia & MDS, H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida
Rami Komrokji, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI BioPharma; Geron; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; PharmaEssentia; Rigel Pharmaceuticals, Inc.; Servier Pharmaceuticals; and Taiho Oncology, Inc.
Grant/Research Support from Bristol Myers Squibb.
Speaker for AbbVie; CTI BioPharma; Jazz Pharmaceuticals, Inc.; PharmaEssentia; and Servier Pharmaceuticals.
Cecilia CS Yeung, MD
Associate Professor, Clinical Research Division Fred Hutch Cancer Center Associate Professor, Dept. of Laboratory Medicine and Pathology University of Washington Medical Director, Fred Hutch Clinical Testing Laboratories Seattle, Washington
Cecilia CS Yeung, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Twinstrand Biosciences.
Speaker for Blueprint Medicines and Lilly.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is supported through an educational grant from Bristol Myers Squibb.
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Certification Statement
ABPath The activity titled “Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.